CN108349904B - Ppar激动剂、化合物、药物组合物及其使用方法 - Google Patents

Ppar激动剂、化合物、药物组合物及其使用方法 Download PDF

Info

Publication number
CN108349904B
CN108349904B CN201680057879.0A CN201680057879A CN108349904B CN 108349904 B CN108349904 B CN 108349904B CN 201680057879 A CN201680057879 A CN 201680057879A CN 108349904 B CN108349904 B CN 108349904B
Authority
CN
China
Prior art keywords
methyl
compound
pharmaceutically acceptable
imidazol
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680057879.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108349904A (zh
Inventor
M·唐斯
R·M·埃文斯
A·克鲁格
B·拉古
三浦理宪
S·K·潘尼格拉西
M·帕塔内
S·萨玛杰达尔
R·瑟耐尔
高桥泰辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellai Engineering Small Molecule Usa Co ltd
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108349904(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Institute for Biological Studies, Mitobridge Inc filed Critical Salk Institute for Biological Studies
Priority to CN202110286947.3A priority Critical patent/CN113024467B/zh
Priority to CN202110284826.5A priority patent/CN113004205B/zh
Publication of CN108349904A publication Critical patent/CN108349904A/zh
Application granted granted Critical
Publication of CN108349904B publication Critical patent/CN108349904B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680057879.0A 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法 Active CN108349904B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110286947.3A CN113024467B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN202110284826.5A CN113004205B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562238629P 2015-10-07 2015-10-07
US62/238,629 2015-10-07
US201562243263P 2015-10-19 2015-10-19
US62/243,263 2015-10-19
US201662352348P 2016-06-20 2016-06-20
US62/352,348 2016-06-20
PCT/US2016/055521 WO2017062468A1 (en) 2015-10-07 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110284826.5A Division CN113004205B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN202110286947.3A Division CN113024467B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Publications (2)

Publication Number Publication Date
CN108349904A CN108349904A (zh) 2018-07-31
CN108349904B true CN108349904B (zh) 2021-08-31

Family

ID=57200096

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110286947.3A Active CN113024467B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN202110284826.5A Active CN113004205B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN201680057879.0A Active CN108349904B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202110286947.3A Active CN113024467B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN202110284826.5A Active CN113004205B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Country Status (26)

Country Link
US (6) US10399958B2 (enExample)
EP (3) EP3359528B1 (enExample)
JP (2) JP6657413B2 (enExample)
KR (2) KR102667385B1 (enExample)
CN (3) CN113024467B (enExample)
AU (3) AU2016333963C1 (enExample)
BR (1) BR112018006866B1 (enExample)
CA (1) CA3000431A1 (enExample)
CO (1) CO2018004473A2 (enExample)
DK (1) DK3359528T3 (enExample)
EA (1) EA037371B1 (enExample)
ES (3) ES2949852T3 (enExample)
HU (1) HUE058154T2 (enExample)
IL (3) IL258225B (enExample)
JO (3) JO3738B1 (enExample)
MA (2) MA52098A (enExample)
MX (3) MX392524B (enExample)
MY (1) MY203081A (enExample)
PH (1) PH12018500762A1 (enExample)
PL (1) PL3359528T3 (enExample)
PT (1) PT3359528T (enExample)
SG (1) SG10201906400SA (enExample)
TW (3) TWI730408B (enExample)
UA (1) UA122237C2 (enExample)
WO (1) WO2017062468A1 (enExample)
ZA (4) ZA201802029B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113004205B (zh) * 2015-10-07 2024-07-02 米托布里奇公司 Ppar激动剂、化合物、药物组合物及其使用方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018069930B1 (pt) 2016-04-13 2024-02-20 Mitobridge, Inc Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica
PL3523283T3 (pl) * 2016-10-05 2021-12-13 Mitobridge, Inc. Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar
MY192385A (en) * 2016-10-05 2022-08-18 Mitobridge Inc Methods of treating acute kidney injury
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
EP4346807A1 (en) 2021-06-02 2024-04-10 Astellas Pharma Inc. Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
WO2025207099A1 (en) 2024-03-28 2025-10-02 Astellas Pharma Inc. Ppar-delta inhibitors for preventing post-operative atrial fibrillation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085772A (zh) * 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
WO2014165827A1 (en) * 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057322A1 (en) * 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228281A (en) 1977-09-23 1980-10-14 Ciba-Geigy Corporation Dicarboxylic acids containing triazine rings
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
IL144781A0 (en) 1999-02-26 2002-06-30 Merck & Co Inc Novel sulfonamide compounds and uses thereof
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
MXPA03001425A (es) 2000-08-17 2003-06-06 Pfizer Compuestos farmaceuticos.
DK1537078T3 (da) * 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
EP2319509A1 (en) 2003-09-26 2011-05-11 Japan Tobacco, Inc. Method of Inhibiting remnant lipoprotein production
WO2006027135A1 (en) 2004-09-06 2006-03-16 F. Hoffmann-La Roche Ag 4-aminomethyl benzamidine derivatives and their use as factor viiia inhibitors
WO2007028424A1 (en) 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Amide derivatives as ppar activators
RU2008108221A (ru) 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
EA019385B1 (ru) 2006-01-30 2014-03-31 ТРАНСТЕК ФАРМА ЭлЭлСи ЗАМЕЩЕННЫЕ ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ РТРазы
JP2009531364A (ja) 2006-03-28 2009-09-03 ノバルティス アクチエンゲゼルシャフト アミド誘導体およびｇタンパク質関連疾患の処置のためのそれらの使用
JP5290749B2 (ja) 2006-04-18 2013-09-18 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
WO2009086526A2 (en) 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
AU2008221718A1 (en) 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
JP2008285452A (ja) 2007-05-21 2008-11-27 Ono Pharmaceut Co Ltd ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
ES2607482T3 (es) 2012-08-28 2017-03-31 Koc Universitesi Placa ósea
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
MX392524B (es) 2015-10-07 2025-03-24 Salk Inst Biological Studies Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
BR112018069930B1 (pt) 2016-04-13 2024-02-20 Mitobridge, Inc Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica
PL3523283T3 (pl) * 2016-10-05 2021-12-13 Mitobridge, Inc. Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar
MY192385A (en) 2016-10-05 2022-08-18 Mitobridge Inc Methods of treating acute kidney injury
EP3562822B1 (en) * 2016-12-30 2021-03-10 Mitobridge, Inc. Poly-adp ribose polymerase (parp) inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085772A (zh) * 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
WO2014165827A1 (en) * 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057322A1 (en) * 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113004205B (zh) * 2015-10-07 2024-07-02 米托布里奇公司 Ppar激动剂、化合物、药物组合物及其使用方法
CN113024467B (zh) * 2015-10-07 2024-08-06 米托布里奇公司 Ppar激动剂、化合物、药物组合物及其使用方法

Also Published As

Publication number Publication date
JOP20200231A1 (ar) 2022-10-30
CN113004205A (zh) 2021-06-22
MX392524B (es) 2025-03-24
US20190084958A1 (en) 2019-03-21
ZA201802029B (en) 2022-01-26
EP3795566B1 (en) 2023-04-19
HUE058154T2 (hu) 2022-07-28
IL275392A (en) 2020-07-30
CN108349904A (zh) 2018-07-31
MX2018004295A (es) 2018-08-09
US20240417383A1 (en) 2024-12-19
IL275392B (en) 2022-05-01
ZA202003664B (en) 2022-08-31
JOP20200230A1 (ar) 2022-10-30
US20210253549A1 (en) 2021-08-19
AU2020281069A1 (en) 2021-01-07
US20230373948A1 (en) 2023-11-23
UA122237C2 (uk) 2020-10-12
MY203081A (en) 2024-06-07
TW201722919A (zh) 2017-07-01
TW202012375A (zh) 2020-04-01
WO2017062468A1 (en) 2017-04-13
AU2019283837A1 (en) 2020-01-16
KR102667385B1 (ko) 2024-05-21
MA52098A (fr) 2021-01-27
KR20180095797A (ko) 2018-08-28
ES2949852T3 (es) 2023-10-03
PL3359528T3 (pl) 2022-05-30
JP6657413B2 (ja) 2020-03-04
CN113004205B (zh) 2024-07-02
WO2017062468A8 (en) 2017-05-11
BR112018006866A2 (pt) 2018-10-16
EP3770146B1 (en) 2024-07-24
US10479775B1 (en) 2019-11-19
JP6866514B2 (ja) 2021-04-28
AU2019283837B2 (en) 2020-12-24
PT3359528T (pt) 2022-04-07
ES2988059T3 (es) 2024-11-19
JO3738B1 (ar) 2021-01-31
HK1257907A1 (zh) 2019-11-01
JP2020075939A (ja) 2020-05-21
AU2016333963B2 (en) 2021-01-07
ZA202003663B (en) 2022-08-31
IL275387A (en) 2020-07-30
AU2020281069B2 (en) 2022-10-27
MX2020011100A (es) 2022-05-23
IL258225A (en) 2018-05-31
JP2018534355A (ja) 2018-11-22
NZ740846A (en) 2024-12-20
US11578052B2 (en) 2023-02-14
TWI730006B (zh) 2021-06-11
EP3770146C0 (en) 2024-07-24
BR112018006866B1 (pt) 2023-11-21
EA037371B1 (ru) 2021-03-19
TWI742479B (zh) 2021-10-11
ES2906379T3 (es) 2022-04-18
AU2016333963C1 (en) 2021-05-27
CN113024467B (zh) 2024-08-06
EP3359528B1 (en) 2022-01-12
EA201890776A1 (ru) 2018-09-28
MX392523B (es) 2025-03-24
KR20210126150A (ko) 2021-10-19
CO2018004473A2 (es) 2018-09-20
SG10201906400SA (en) 2019-08-27
CN113024467A (zh) 2021-06-25
MA52648A (fr) 2021-10-13
EP3770146A1 (en) 2021-01-27
ZA202003662B (en) 2022-08-31
DK3359528T3 (en) 2022-03-07
EP3795566A1 (en) 2021-03-24
US10399958B2 (en) 2019-09-03
KR102667386B1 (ko) 2024-05-21
MX2020011099A (es) 2022-05-23
MX380281B (es) 2025-03-12
US20190337920A1 (en) 2019-11-07
US10906885B2 (en) 2021-02-02
AU2016333963A1 (en) 2018-04-12
TW201943705A (zh) 2019-11-16
CA3000431A1 (en) 2017-04-13
US20200157074A1 (en) 2020-05-21
TWI730408B (zh) 2021-06-11
EP3359528A1 (en) 2018-08-15
PH12018500762A1 (en) 2018-10-29
IL275387B (en) 2021-08-31
IL258225B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
CN108349904B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK1257907B (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
HK40054571B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054571A (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054101B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054101A (zh) Ppar激动剂、化合物、药物组合物及其使用方法
EA039833B1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257907

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Massachusetts, USA

Patentee after: Astellai Engineering Small Molecule USA Co.,Ltd.

Country or region after: U.S.A.

Patentee after: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

Address before: Massachusetts, USA

Patentee before: MITOBRIDGE, Inc.

Country or region before: U.S.A.

Patentee before: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

CP03 Change of name, title or address
TR01 Transfer of patent right

Effective date of registration: 20241231

Address after: California, USA

Patentee after: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: Astellai Engineering Small Molecule USA Co.,Ltd.

Country or region before: U.S.A.

Patentee before: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

TR01 Transfer of patent right